Table 3.
Comparisons of combined questionnaire and urine data by usage status
| Variable | Non-users n=200 (90%) Mean (SD) |
Users n=22 (10%) Mean (SD) |
p |
|---|---|---|---|
| Age (years) | 71.48 (10.18) | 64.36 (9.85) | 0.002 |
| Years on ADT | 3.28 (3.15) | 2.19 (3.07) | 0.010 |
| Type of ADT | 0.626 | ||
| Eligard (Leuprolide) | 28 (14%) | 6 (27%) | |
| Firmagon (Degarelix) | 10 (5%) | 0 | |
| Lupron (Leuprolide) | 77 (38.5%) | 9 (41%) | |
| Suprefact (Buserelin) | 2 (1%) | 0 | |
| Trelstar (Triptorelin) | 12 (6%) | 1 (5%) | |
| Zoladex (Goserelin) | 67 (33.5%) | 6 (27%) | |
| Casodex (Biclutamide) | 4 (2%) | 0 | |
| Most recent testosterone level (nmol/L) | 0.85 (1.29) | 0.48 (0.42) | 0.003 |
ADT: androgen-deprivation therapy; SD: standard deviation.